A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC#801708) in combination with fludarabine and cytarabine for patients with acute myeloidleukemia, myelodysplastic syndrome or mixed phenotype acute leukemia thatexpresses E-selectin ligand on the cell membrane and is in second or greater relapseor that is refractory to relapse therapy
PEPN2113: Study of Uproleselan in Children with AML, MDS, or MPAL
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAU8473
U.S. Govt. ID: NCT05146739
Contact: Nobuko Hijiya, MD: / nh2636@cumc.columbia.edu
Additional Study Information: This is a Phase 1 study of a drug called uproleselan. We are testing new experimental drugs such as uproleselan in the hopes of finding a treatment that may be effective against acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that has come back or that has not responded to standard therapy. This study looks at how well uproleselan works when given to children and young adults with relapsed or refractory leukemia. Uproleselan is experimental because it has not been proven to work in this type of situation. We are using uproleselan because it seems to work against cancer in test tubes and animals. Uproleselan has been used in adults and there is a lot that we do not know about it yet.
Nobuko Hijiya, MD
Do You Qualify?
Have you or your child been diagnosed with AML, MDS, or MPAL? Yes No
Are you or your child under the age of 18? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Nobuko Hijiya, MD